Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

["Clinically significant" new drug interactions].

U Fuhr1

  • 1Klinische Pharmakologie, Universität zu Köln. uwe.fuhr@medizin.uni-koeln.de

Medizinische Klinik (Munich, Germany : 1983)
|April 9, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.

European journal of endocrinology·2018
Same author

Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.

Cancer chemotherapy and pharmacology·2015
Same author

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler.

European journal of clinical pharmacology·2013
Same author

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

European journal of clinical pharmacology·2012
Same author

Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.

European journal of clinical pharmacology·2011
Same author

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.

Clinical pharmacology and therapeutics·2010
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2014
See all related articles

Drug interactions are common, but severe adverse effects are rare. Evaluating clinical relevance is challenging, so avoid stopping beneficial drug combinations unless safer alternatives exist.

Area of Science:

  • Pharmacology and Clinical Pharmacy
  • Drug Metabolism and Pharmacokinetics
  • Drug Safety and Pharmacovigilance

Context:

  • Concomitant drug intake is frequent, yet adverse effects from drug interactions represent a small fraction of all adverse events.
  • A reproducible method for evaluating the clinical relevance of drug interactions is currently lacking.
  • Drug interaction potential can be defined using comparative investigations within drug classes.

Purpose:

  • To address the lack of reproducible evaluation methods for the clinical relevance of drug interactions.
  • To discuss the utility of drug interaction information in clinical decision-making.
  • To provide examples of drug interactions with commonly used medications and substances.

Summary:

  • Drug interactions are frequent, but severe adverse effects are uncommon, indicating a need for better clinical relevance assessment.

Related Experiment Videos

  • Comparative drug class investigations can define interaction potential, but patient benefit from this information is uncertain.
  • Therapeutically valuable drug combinations with interaction risks should generally be maintained if equivalent options are unavailable.

    • Impact:

    • Highlights the need for improved methodologies to assess the clinical significance of drug-drug interactions.
    • Informs clinical practice regarding the judicious use of drug interaction data in patient care.
    • Provides practical insights through case examples involving selective serotonin re-uptake inhibitors, statins, and other agents.